TSS, Inc. Insider Report: CFO Disposes of 15,000 TSSI Shares
Rhea-AI Filing Summary
Daniel M. Chism, listed as Chief Financial Officer of TSS, Inc. (TSSI), reported sales of company common stock on 08/27/2025 and 08/28/2025. The Form 4 shows a sale of 10,000 shares on 08/27/2025 at a weighted average price of $16.25 and a sale of 5,000 shares on 08/28/2025 at $16.20. The report records beneficial ownership of 316,219 shares following the 08/27 sale and 311,219 shares following the 08/28 sale. The filing is signed by an attorney-in-fact, Christopher R. Johnson, dated 08/29/2025. The filer affirms willingness to provide transaction-level price details within the disclosed price range.
Positive
- Timely disclosure: Form 4 was filed with signature dated 08/29/2025, providing required insider sale reporting.
- Detailed pricing footnote: The filer offers to supply per-trade prices within the disclosed weighted-average range, enhancing transparency.
Negative
- Officer dispositions: The Chief Financial Officer sold a total of 15,000 shares across two days, reducing reported beneficial ownership from 316,219 to 311,219 after the second sale.
- No indication of plan-based sales: The form does not indicate these sales were made pursuant to a Rule 10b5-1 plan, which some investors use to reduce concerns about timing.
Insights
TL;DR: Company CFO sold 15,000 TSSI shares across two days; filings disclose post-sale ownership and weighted average sale prices.
The Form 4 documents two non-derivative dispositions by CFO Daniel M. Chism totaling 15,000 common shares executed on 08/27/2025 and 08/28/2025. Reported prices are a weighted average of $16.25 for the first date and $16.20 for the second; the filer notes transaction prices ranged from $16.245 to $16.26 for the 08/27 sales. Beneficial ownership is recorded as 316,219 shares after the 08/27 sale and 311,219 after the 08/28 sale. The filing is executed by an attorney-in-fact on 08/29/2025, indicating formal disclosure compliance. No other transactions, derivates, or plan-based sales are disclosed in this Form 4.
TL;DR: Insider sales were disclosed promptly and show a modest reduction in CFO's holdings; no derivative activity or plan-based sale indicated.
The filing indicates straightforward open-market dispositions rather than exercises or derivative transactions. The report includes a disclosure footnote offering to provide per-trade price details, which increases transparency. There is no evidence in this filing of Rule 10b5-1 plan sales or of any unusual related-party transactions. Based solely on the Form 4 content, the transaction appears to be a routine sale by an officer with post-transaction holdings clearly stated.